Hybridon deal

Hybridon (Worcester, Mass.) and Pharmacia AB will develop a large-scale oligonucleotide synthesis system for use in full-scale commercial production of Hybridon’s antisense oligonucleotide, GEM 91. The product is in Phase II trials in the U.S. and France to treat HIV and AIDS. ...